Breast cancer drug could treat rare childhood brain tumours
Ribociclib – a drug already used to treat breast cancer – may help slow the growth of diffuse hemispheric glioma (DHG), new research has found.
A team of scientists from The Institute of Cancer Research, London and the Dana-Farber Cancer Institute, Boston, USA, have uncovered clues about the growth of a specific type of DHG – DHG, H3G34-mutant – which allowed them to explore new targeted treatments.
Diffuse hemispheric glioma is a rare, high-grade childhood brain tumour with a prognosis of 18-22 months; there is currently no cure. It is estimated that more than 30% of all paediatric high-grade glioma diagnoses are the DHG-H3G34 variant.
Laboratory tests and pre-clinical models led the researchers to discover that tumour cells disrupt the normal development of neurons, causing them to look like immature early neuron-like cells.
They found that targeting the protein CDK6, which is involved in regulating cell division, could prove promising. Abnormal activity in the CDK6 protein can lead to uncontrolled cell division – a hallmark of cancer.
Ribociclib is a CDK4/6 inhibitor approved to treat breast cancer, but treatment in a child with a brain tumour resulted in stable disease for a further 17 months until it started to grow back.
Ribociclib, sold under the brand name Kisqali, is a kinase inhibitor that was developed by Novartis and Astex Pharmaceuticals.
Targeted treatment for DHG-H3G34 tumours
This research also showed that DHG-H3G34 tumours are more responsive to CDK4/CDK6 inhibitors than other high-grade glioma types – opening the door for more targeted treatments for this genetically distinct tumour type.
Professor Chris Jones, Professor of Childhood Brain Tumour Biology at The Institute of Cancer Research, London, said: “This work shows the importance of understanding how brain tumours develop in order to figure out better ways to treat these patients. It was a surprise to realise that this type of glioma seemed to arise from developing neurons, but we were able to use this knowledge to find specific vulnerabilities in these cancer cells, which hopefully we can now translate into clinical trials.”
Mariella Filbin, Co-Director of the Paediatric Neuro-Oncology Program at Dana-Farber Cancer Institute, added: “Our trans-Atlantic collaboration helped tremendously in validating and expanding our results, and I am thrilled to see our work translate into helping a patient so quickly. This is the first time we found functional consequences of aberrant lineage specification in tumour cells – a result that was unexpected at first, but is now setting the stage for new therapeutic avenues in this disease.”
Diana Spencer, Senior Digital Content Editor, DDW
